VET1 S3
Alternative Names: VET1-S3Latest Information Update: 12 Nov 2021
At a glance
- Originator KaliVir Immunotherapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; STAT3 transcription factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 12 Nov 2021 KaliVir Immunotherapeutics has two US patents relating to two separate licensed technologies which support VET™ platform
- 24 Mar 2021 VET1 S3 is available for licensing as of 10 Dec 2020. https://kalivir.com/#pipeline
- 10 Dec 2020 Preclinical trials in Solid tumours in USA (IV) before December 2020 (KaliVir Immunotherapeutics pipeline, December 2020)